Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05870748
Title REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Sutro Biopharma, Inc.
Age Groups: adult | senior
Covered Countries USA | AUS

No variant requirements are available.